Pre-vaccination transcriptomic profiles of immune responders to the MUC1

2

peptide vaccine for colon cancer prevention

3

Cheryl M. Cameron^{1†}, Vineet Raghu^{2,3†}, Brian Richardson^{1,4†}, Leah L. Zagore⁴, 4 5 Banumathi Tamilselvan¹, Jackelyn Golden⁴, Michael Cartwright⁴, Robert E. Schoen⁵, Olivera J. Finn^{6*}, Panayiotis V. Benos^{7,8*}, Mark J. Cameron^{4*} 6 7 8 9 ¹ Department of Nutrition, Case Western Reserve University, Cleveland, OH ² Department of Computer Science, University of Pittsburgh, Pittsburgh, PA 10 ³ Massachusetts General Hospital, Harvard Medical School, Cambridge, MA 11 ⁴ Department of Population and Quantitative Health Sciences, Case Western 12 Reserve University, Cleveland, OH 13 14 ⁵ Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh, 15 Pittsburgh, PA ⁶ Department of Immunology, University of Pittsburgh, Pittsburgh, PA 16 ⁷ Department of Epidemiology, University of Florida, Gainesville, FL 17 ⁸ Department of Computational and Systems Biology, University of Pittsburgh, 18 19 Pittsburah. PA 20 [†] Contributed equally 21 * Co-corresponding authors 22 23 24 Keywords: colon cancer, colorectal adenoma, cancer vaccine, transcriptomics, MUC1, 25 26 serological response 27

28 Abstract

29 Self-antigens abnormally expressed on tumors, such as MUC1, have been targeted by 30 therapeutic cancer vaccines. We recently assessed in two clinical trials in a preventative 31 setting whether immunity induced with a MUC1 peptide vaccine could reduce high colon 32 cancer risk in individuals with a history of premalignant colon adenomas. In both trials, 33 there were immune responders and non-responders to the vaccine. Here we used PBMC 34 pre-vaccination and 2 weeks after the first vaccine of responders and non-responders 35 selected from both trials to identify early biomarkers of immune response involved in long-36 term memory generation and prevention of adenoma recurrence. We performed flow 37 cytometry, phosflow, and differential gene expression analyses on PBMCs collected from 38 MUC1 vaccine responders and non-responders pre-vaccination and two weeks after the 39 first of three vaccine doses. MUC1 vaccine responders had higher frequencies of CD4 40 cells pre-vaccination, increased expression of CD40L on CD8 and CD4 T-cells, and a 41 greater increase in ICOS expression on CD8 T-cells. Differential gene expression 42 analysis revealed that iCOSL, PI3K AKT MTOR, and B-cell signaling pathways are 43 activated early in response to the MUC1 vaccine. We identified six specific transcripts 44 involved in elevated antigen presentation, B-cell activation, and NF-kB1 activation that 45 were directly linked to finding antibody response at week 12. Finally, a model using these 46 transcripts was able to predict non-responders with accuracy. These findings suggest that 47 individuals who can be predicted to respond to the MUC1 vaccine, and potentially other 48 vaccines, have greater readiness in all immune compartments to present and respond to 49 antigens. Predictive biomarkers of MUC1 vaccine response may lead to more effective 50 vaccines tailored to individuals with high risk for cancer but with varying immune fitness.

51 Introduction

52 Self-antigens abnormally expressed in tumors, known as non-viral cancer-associated 53 antigens, have been extensively tested over the last three decades as antigens in 54 therapeutic cancer vaccines (1-3). In preclinical studies, an immune response to these 55 antigens can prevent cancer growth without causing toxicity. In humans, preexisting 56 immunity to some such antigens correlates with better disease outcome or reduced risk 57 of cancer recurrence (4). Nevertheless, therapeutic vaccines utilizing these antigens 58 have had low immunogenicity and no clinical efficacy. This has been attributed to the 59 presence of many immunosuppressive influences in the tumor microenvironment (5, 6). 60 MUC1 is a cancer-associated antigen that has been effective as a vaccine in preclinical 61 animal models but showed limited immunogenicity and efficacy as a therapeutic vaccine 62 in clinical trials in colon, breast, pancreas, prostate and lung cancer (7-11). Hypothesizing that the major difference between the outcome of the vaccine in preclinical models and 63 64 clinical trials is the high level of immune suppression in cancer patients, we began to 65 develop models and MUC1 vaccines for cancer prevention in patients at risk; before 66 immune suppression develops. As MUC1 is expressed on early premalignant lesions as 67 well as cancer, we chose to study immunogenicity, safety and potential efficacy of this 68 vaccine in the preventative setting in individuals with a history of colonic polyps that 69 increases their risk of colon cancer (12).

From 2008 to 2012, we conducted a single arm trial (NCT-007773097) (13) in 41 individuals. Forty-three percent (43%) of vaccinated participants responded to the vaccine as measured by production of anti-MUC1 IgG at week 12 post vaccination (vaccine responders), and 57% did not respond (vaccine non-responders). From 2015-2020, we

74 conducted the second study, a randomized, double-blind placebo-controlled multi-center 75 efficacy trial of the same MUC1 vaccine in the setting of newly diagnosed advanced 76 adenomas in 110 individuals (NCT-02134925) (14). Twenty-seven percent (27%) of the 77 vaccinated participants responded to the vaccine. In addition to the immune response, in 78 this trial we evaluated adenoma recurrence by follow-up colonoscopy ≥ 1 year from the 79 start of vaccination. In vaccine responders, adenoma recurrence was reduced by 38% 80 compared to non-responders and placebo controls. Predictable factors such as gender, 81 age, and HLA-type were not significantly different between vaccine responders and non-82 It became important to understand why some individuals mounted a responders. 83 potentially protective immune response, while others did not, having the same diagnosis.

84 In this study, we analyzed PBMC samples collected from both trials at baseline (pre-85 vaccination) and 2 weeks post-first of 3 vaccines (week 0, week 2 and week 10) from 86 vaccine responders and non-responders and identified comprehensive gene and 87 pathway biomarkers related to vaccine response. We discovered that several key T- and 88 B-cell cellular proliferation and stress pathways were enriched in responders, while 89 oxidative phosphorylation and DNA damage response and repair pathways were 90 enriched in non-responders. Responders had higher frequencies of CD4 cells at baseline. 91 with higher activation and/or costimulatory signaling in CD8 and CD4 T-cells from 92 baseline to week 2 in CD8 T-cells. Phosflow analysis revealed enhanced phosphorylation 93 of B-cell signaling molecules and T-cell help targets in responders at baseline and a 94 significant increase in NFkB phosphorylation in B-cells at week 2. Lastly, we applied 95 graphical modeling approaches (15-17) to this data and built a regression model to

96 discriminate future responders and non-responders via their predicted and actual IgG
 97 response at week 12.

98 Materials and Methods

99 **PBMC collection**

100 PBMC samples from patients with a history of, or with newly diagnosed, advanced colonic 101 adenoma and at high risk for colon cancer were collected as part of two clinical trials of a 102 MUC1 vaccine registered at clinicaltrials.gov (NCT-007773097, NCT-02134925) (13, 14). 103 The ethics committee/IRB of the following institutions gave ethical approval for this work: 104 Mayo Clinic, Rochester MN; Kansas City Veterans Affairs Medical Center, Kansas City, 105 KS: University of Pittsburgh Medical Center, Pittsburgh PA: University of Puerto Rico, 106 San Juan PR; Thomas Jefferson University Hospital, Philadelphia PA; and 107 Massachusetts General Hospital, Boston MA. All participants provided written informed 108 consent. Blood samples were processed within 24 hours by the same individual, using 109 the same protocol. Heparinized blood was layered on lymphocyte separation medium 110 (MPbio) and centrifuged at 800 g for 10 min with lowest acceleration and deceleration 111 speed. PBMC were collected from the interphase, washed twice, resuspended in 80% 112 human serum and 20% DMSO, and stored in liquid nitrogen.

113

114 **RNA-Seq**

PBMC samples were thawed, pelleted, and lysed in 350 uL of RLT with betamercaptoethanol. RNA was isolated using the RNeasy Mini kit (Qiagen). RNA quality was assessed with the Fragment Analyzer (Agilent) and its Standard Sensitivity RNA kit. Total RNA was normalized to 100 ng prior to random hexamer priming and libraries generated

by the TruSeq Stranded Total RNA – Globin kit (Illumina). The resulting libraries were assessed on the Fragment Analyzer (Agilent) with the High Sense Large Fragment kit and quantified using a Qubit 3.0 fluorometer (Life Technologies. Medium depth sequencing (>30 million reads per sample) was performed with a HiSeq 2500 (Illumina) on a High Output, 125 base pair, Paired End run.

124

125 **Bioinformatic analysis**

126 Raw demultiplexed fastq paired end read files were trimmed of adapters and filtered using 127 the program skewer (18), discarding those with an average phred quality score <30 or a 128 length <36. Trimmed reads were aligned to human reference genome GRCh38 using 129 HISAT2(19) and sorted using SAMtools (20). Aligned reads were counted and assigned 130 to gene meta-features using the program featureCounts (21) as part of the Subread 131 package. Quality control, normalization and analysis were performed in R, using an in-132 house pipeline utilizing the limma-trend method for differential gene expression testing 133 and the GSVA (22) library for gene set sample enrichment. Final differential gene 134 expression lists were filtered to remove non-coding RNAs as well as LOC features. The 135 datasets for this study can be found in the Gene Expression Omnibus (GEO) public 136 database with the accession number pending.

137

138 Flow cytometric analysis

For immune cell phenotyping and assessment of intracellular levels of bcl2, and phosphorylation of STAT3, erk1/2, NF-kB and MTORC targets, cells were first stained with Live/Dead Aqua (Invitrogen) followed by cocktails of monoclonal antibodies

142 recognizing the following cell surface markers: CD4, CD8, CD45RA, CD27, CCR7, 143 CD152, CD86, CD275, CD11c, CD56, CD16, CD19, CD3, HLA-DR, CD14, CD40, and 144 CD11b. Cells were washed, fixed and permeabilized, then stained with antibodies specific for the following intracellular proteins: NFkB p65, erk1/2 (pT202/pY204), STAT3 (pY705), 145 146 Akt1, pS6 (S235/236 & S240) and p4E-BP1 (T36/46). Cells were washed and fixed and 147 events were collected on a BD ARIA-SORP instrument. A 15-minute incubation at 37C with recombinant human IL-6 (100ng/mL) (BD Pharmingen) was performed to induce 148 149 NFkB signaling. After washing, cells were resuspended in staining buffer and sorted on 150 an ARIA-SORP. Data was analyzed using FlowJo software (TreeStar).

151

152 **Predictive model for post-vaccination immune response**

A detailed explanation of computational model development and evaluation can be found in the supplemental methods. Briefly, a LASSO logistic regression (23) was used to develop a prediction model for a binary outcome of response defined by the clinical trial endpoint (\geq 2-fold increase in IgG from baseline to week 12), using transcriptomic data measured two-weeks post-vaccination (Week 2 data). A Mixed Graphical Models (MGM) algorithm was used to infer a unidirectional graphical model followed by FCI-MAX to determine direction. All statistical analysis was performed in R.

160

161 Statistics

162 Unless otherwise indicated, the Student's t-test was used, with $p \le 0.05$ chosen as the 163 level of significance.

164

165 **Results**

Vaccine responders and non-responders show differential gene expression in PBMCs pre-vaccination

168 Next-generation RNA-seg analysis was performed on PBMCs from 46 participants of the 169 two trials, conducted in the same setting of advanced adenoma and with the identical 170 vaccine and vaccination protocol. The vaccine, composed of 100µg of MUC1 peptide plus 171 the polyICLC adjuvant Hiltonol®, was administered at week 0, 2, 10 and 52. We assayed 172 PBMC samples collected at the time of the first injection (baseline) and 2 weeks later, at 173 the time of the second injection in order to be able to define preexisting (at baseline) and 174 early post-vaccination (week 2) signatures of response to MUC1 vaccination. Vaccine 175 responders (R, n=13) in both trials were defined as having anti-MUC1 IgG levels at week 176 12 (after all three injections) at least two-fold higher than baseline. For some of our 177 analyses we also classified responders by antibody levels into high responders (HR, anti-178 MUC1 IgG OD450 at 1:80 plasma dilution ≥0.4), low responders (LR, OD450 at 1:80 179 plasma dilution <0.4), and non-responders (NR) (no difference from baseline).

180 RNA-seq performed on PBMCs collected immediately pre-vaccination (baseline) 181 revealed a total of 2,321 genes that were differentially expressed between all responders 182 and all non-responders at baseline (Fig 1A). Within these genes, 1,337 showed increased 183 transcript levels and 984 showed decreased levels. Among the top 50 differentially 184 expressed genes by p-value (Fig 1B), 47 genes were upregulated in responders 185 compared to non-responders. The upregulated genes were involved in transcriptional and 186 epigenetic regulation, including multiple subunits of the SWI/SNF chromatin remodeling 187 complex (ARID1A, ARID1B, and SMARCC2), as well as NCOA6, a multifunctional

188 transcriptional coactivator and component of the Set1-like H3K4-methyltransferase 189 complex ASCOM, all of which have been shown to play a role in the pathogenesis of 190 cancer (24). Additional cancer-relevant transcriptional regulators higher in responders 191 before vaccination include SP2, NFYC, AKNA, MYPOP, and ZNF652. CUX1 is a subunit 192 of the NF-muNR repressor that binds to the matrix attachment regions of the 193 immunoglobulin heavy chain enhancer and the TCR enhancer. The epigenetic regulator 194 HCFC1 tethers Set and Sin3 histone modifying complexes together and was also higher 195 in responders at baseline (25). We observed an increase in TRAPPC9, an activator of 196 NFkB, and FAM168A, which is involved in the PI3K/AKT/NFkB signaling pathway. 197 RRAGA was one of 3 downregulated genes among the top differentially expressed genes 198 in responders and plays a role in regulating the mTORC1 complex (26). The presence of 199 transcriptional and epigenetic regulators within the list of upregulated genes could explain the large number of significant changes in steady-state RNA levels we observed and 200 201 suggests a differing global transcriptional program between responders and non-202 responders before vaccination. As these upstream regulators have the potential to 203 broadly remodel the transcriptome, they may represent potent therapeutic targets.

Vaccine responders and non-responders show differences in gene expression in PBMCs at week 2 post-vaccination

At two weeks post-first injection, we found 1,887 genes differentially expressed in responders vs. non-responders, 934 genes upregulated and 953 genes downregulated (Fig 1C). The top 50 genes arranged by p-value are shown in Figure 1D. Among the upregulated genes are several cancer-related transcriptional regulators including PPARD

210 (27) and HMGA1 (28), key regulators of lipid pathways (29), transcription elongation 211 factor SPT6 (SUPT6H), SOAT2, an enzyme involved in lipoprotein and cholesterol 212 regulation, and GPD1, an enzyme that plays a key role in lipid metabolism, are also 213 upregulated in responders. Among the downregulated cancer-related genes we found 214 five involved in mitosis and G2/M DNA replication checkpoint, the kinesin-like proteins 215 KIF11 and KIF15 (30), centromere/centrosome proteins CENPF and CEP55 (31), and the 216 cell cycle regulator protein DLGAP5 (32). Importantly, CEP55 and DLGAP5 are key 217 predictors of antibody response in our graphical model discussed below.

We then performed double contrast analysis of the genes that were significantly differentially changed from baseline to week 2 in the responders vs. non-responders (Fig 1E). The top 50 genes by p-value (Fig 1F) are enriched in immune-related genes. IFNL1 is upregulated in contrast to CD38 and IL12RB2, which are downregulated in responders. Again, selective upregulation of transcriptional and epigenetic regulators in responders is evident; examples include PRDM5, ZNF230, ZCCHC9, ZKSCAN4, and the epigenetic regulator ALKBH3, which demethylates DNA and RNA in cancer cells (33).

ICOS/ICOSL signaling is differentially associated with response to the MUC1 vaccine

We performed gene set variation analysis (GSVA) of the baseline gene expression data to identify biological pathways regulating the response to vaccination. Vaccine responders displayed significant upregulation of genes involved in the ICOS-ICOSL pathway in T-helper Cells signaling pathway, with increased expression of multiple genes both at baseline and week 2 post-vaccination (Fig 2A and 2B, respectively). At baseline,

responders expressed higher levels of ICOSL, IL2RB, and CD4 coreceptor genes, while
at week 2 post-vaccination higher levels of the downstream NFKB pathway genes
including NFKB2, RELB and RELA were evident.

By flow cytometry, we determined that higher frequencies of CD4 T-cells were present in responders at baseline, potentially related to enhanced ICOSL signaling (Fig 2C). We also detected differences in expression levels of key proteins in this pathway. Higher levels of expression of CD40L were evident in CD4 and CD8 cells (Fig 2D and 2E respectively). Greater increases in ICOS expression were detected post-vaccination inCD8 T-cells of responders. (Fig 2F).

241 mTOR signaling is upregulated in responders to MUC1 vaccination

As many components of the ICOS/ICOSL pathway were significantly higher in the responders vs. non-responders, we focused on differences in the mTOR signaling pathway which lies directly downstream of ICOS/ICOSL engagement. Top enriched pathways in high responders vs. non-responder comparisons included PI3K/AKT/MTOR signaling, WNT/beta-catenin signaling and hedgehog signaling (Fig 3A). In contrast, the Myc targets V1 pathway and DNA repair were negatively associated in high responders.

To validate enhanced mTOR signaling in responders, we developed a phosflow-based panel of antibodies (see Materials and Methods) to measure the phosphorylation levels of RPS6, a commonly used readout of mTORC1 activity. There was a greater increase in RPS6 phosphorylation in CD4 and CD8 T-cells, B-cells (CD19), and monocytes (CD14) of responders, an observation validating our finding at the phosphoprotein level (Fig 3B).

We also performed intracellular staining targeting the phosphorylated AKT1 kinase upstream of the MTORC1 signaling complex. Similarly, we found a greater increase in AKT1 phosphorylation in responders compared to non-responders.

B-cell signaling and enhanced antigen presentation signatures are positively associated with response to MUC1 vaccination

258 As ICOS/ICOSL-mediated signaling promotes fitness of the T lymphocyte compartment, 259 we hypothesized that signaling from the T-cells to the B-cell and APC compartment was 260 also differentially induced. Pathway enrichment analysis of the transcriptomic data 261 revealed significant enrichment of B-Cell Receptor Signaling and PI3K Signaling in B 262 Lymphocytes pathways at baseline (Fig 4A and 4B) and NFkB and CD40 Signaling 263 pathways at baseline and at week 2 post-vaccination (Fig 4C and 4D). CD40 receptor 264 engagement on the surface of antigen presenting cells, such as B-cells, leads to 265 activation of NFkB signaling and enhanced cellular survival and function. Notably, multiple 266 signaling component genes (MAP kinases and Jak3) are significantly upregulated in 267 responders at baseline, followed by upregulation of additional signaling molecules at 268 week two (TRAF1, TRAF3, NFKB1, NFKB2, RELA and RELB).

We validated increased expression of CD40 and HLA-DR on B-cells (CD19+) in responders (Fig 4E) using flow cytometric analyses. We used an intracellular phosflow panel to detect phosphorylation of the p65 subunit of NFκB. We found increased IL6induced NFκB signaling via phosphoryation of p65 in T-cells, HLA-DR+ non-B/non-DC APCs and B-cells of responders (Fig 4F), and B-cells of high responders expressing significantly higher levels of HLADR compared to non-responders (Fig 4E).

275 Finally, we performed gene set variation analysis using the Nakaya et al. vaccine 276 immunogenicity pathway database (34) and determined that a plasmacytoid dendritic cell 277 (DC) signature was already enriched in the PBMCs of responders at baseline (Fig 5A) 278 and further enriched at week 2 post-vaccination (Fig 5B). Vaccine responders showed 279 increased HLA-DR levels on DCs (CD3-, CD19-, HLA-DR+, CD11c+) at baseline (Fig. 280 5C). Responders also showed a greater relative change in CD86 and CD40 expression 281 from baseline to two weeks (Fig 5D-E). Altogether, these results indicate that additional 282 signatures of enhanced antigen presentation are associated with enhance response to 283 MUC1 vaccination.

Six differentially expressed transcripts 2 weeks post-vaccination predict week 12 IgG response to the MUC1 vaccine

286 Based on evidence of key differences in cell populations and molecular pathways 287 between responders and non-responders at baseline and post-vaccination, we 288 hypothesized that some differentially expressed genes may be useful for patient selection 289 and outcome prediction. We tested this hypothesis by applying LASSO regression and 290 MGM-FCI-MAX (17), a graphical modeling algorithm, to 7,968 transcripts meeting a 291 minimal variance threshold. We first performed a cross-validation experiment (see 292 Supplemental Methods) to assess the ability to predict antibody response to the vaccine 293 at week 12, using the transcriptomic signatures at week 2 post-vaccination. Our model 294 achieved an area under the receiver operating characteristic curve (AUROC) value of 295 0.741 to predict response vs. non-response (Fig 6A). At a predicted probability threshold 296 of 0.5, the model achieved a sensitivity of 91.7% (22 predicted responders / 24 true

responders) and a specificity of 36.8% (7 predicted non-responders / 19 true nonresponders). Predicted response odds were correlated with the magnitude of antibody titer at week 12 ($R^2 = 0.209$, p<0.001) (Fig 6B), and with the ratio of IgG titer at week 12 versus baseline ($R^2 = 0.147$, p=0.015).

301 Next, we used graphical models to determine the variables directly linked to week 12 302 antibody titer and distinguish them from simple correlates. We produced a full model with 303 all genes selected in the previous cross-validation experiments, which were learned using 304 the entire week 2 dataset (Fig 6C). Finally, we identified 6 genes that are directly linked 305 to week 12 antibody titer: RP11.81H14.2, CEP55, and TNFSF14 (negatively associated) 306 and C22orf29, DDX12P, and HLA-DQA2 (positively associated) (Fig 6D). The role of 307 these transcripts and how they may contribute to the induction of immune response and 308 vaccine efficacy (discussed below) warrants further investigation.

309 **Discussion**

310 Therapeutic cancer vaccines, tested in numerous clinical trials over several decades, 311 failed to realize the promise generated by the discovery of tumor antigens capable of 312 eliciting humoral and cellular immunity. In most cases, vaccines administered after 313 primary tumor removal failed to boost anti-tumor immunity and prevent tumor recurrence. 314 Ultimately, a greater understanding of the many immunosuppressive forces in the tumor 315 microenvironment helped to explain the reduced efficacy of the rapeutic vaccines. These 316 discoveries support preventative vaccines as an alternative approach to cancer 317 vaccination to reduce cancer risk and incidence as they could be applied in the absence 318 of cancer and cancer-induced immunosuppression. The two clinical trials from which we

319 derived the PBMCs, applied this preventative approach by vaccinating individuals without 320 cancer but at high risk for colon cancer due to advanced colonic adenoma diagnosis (13. 321 14). We expected a vaccine response from most individuals, measured by the production 322 of anti-MUC1 IgG antibodies. It came as a surprise, therefore, that the majority did not 323 respond. However, those who responded had high levels of anti-MUC1 antibodies and 324 established a long-lasting memory response, showing that the vaccine was capable of 325 inducing immunity and response was determined by the individuals receiving the vaccine. 326 Mechanisms underlying this variable response to an apparently efficacious vaccine were 327 not clear.

328 To address this major knowledge gap with an unbiassed approach, we performed RNA-329 seg on total PBMCs from participants in the two MUC1 peptide vaccine trials to identify 330 genes and pathways differentially regulated at baseline as well as post-vaccination in the 331 participants that responded versus those that failed to respond to the vaccine. The 332 analysis revealed that vaccine responders at baseline exhibited an enrichment of key 333 pathways governing survival and proliferation in immune cells, such as mTOR and NFKB 334 signaling, as well as increased frequencies of CD4 and CD8 T-cells. There were more 335 memory CD8 T-cells at baseline and week 2 (post MUC1 vaccine) in responders (Fig 2A 336 and 2E). Responders also had more CD4 T-cells at baseline and higher frequencies of 337 memory CD4 T-cells at week 2 (Fig 2A, 2C, 2D). Other immune compartments appeared 338 to differ in favor of responders with higher levels of BCL2 expression at baseline in CD14+ 339 and greater increases in BCL2 expression at week 2 post-vaccination (data not shown). 340 The control of DC longevity by the regulation of BCL2 directly impacts immune responses.

341 Higher levels of BCL2 suggest enhanced survival in the myeloid compartment and342 consequently better antigen presentation.

343 The differentially expressed genes and pathways that we have identified in vaccine 344 responders and non-responders pre-vaccination and two weeks post-vaccination are top 345 candidates for early biomarkers of vaccine immunogenicity at week 12. Among the six 346 genes directly linked to MUC1 antibody production at week 12, some have already been 347 identified as diagnostic biomarkers (CEP55, TNFSF14) while the others merit deeper 348 investigation as they hold the potential to enhance our understanding of vaccine 349 response. Overexpression of CEP55 has been observed in numerous cancer cell types, 350 including premalignant lesions of the colon (35), and is a known correlate of poor 351 prognosis (36). Notably, a CEP55 peptide vaccine was proposed for breast and colorectal 352 carcinoma immunotherapy as CEP55 is involved in the PI3K/Akt signaling pathway. 353 TNFSF14, also known as LIGHT, functions as a co-stimulatory factor for the activation of 354 lymphoid cells and modulates T-cell proliferation (37, 38). HLA-DQA2 codes for the alpha 355 chain of the HLA-DQ complex and is primarily involved in antigen presentation (37). 356 Interestingly, HLA-DQ phenotypes have been linked with non-responsiveness to hepatitis 357 B vaccination (39). DDX12P is an m⁶A-associated prognostic pseudogene, correlated 358 with favorable outcomes in patients with head and neck squamous cell carcinoma (40). 359 Furthermore, expression patterns of DDX12P were correlated with anti-tumor response 360 and may regulate immune-involved genes through miRNA targeting. RP11-81H14.2 361 (LINC02384) is a long intergenic non-coding RNA primarily expressed in TH1 cells (41). 362 Little is known about the function of LINC02384; however, it has been proposed to act as 363 a competitive endogenous RNA of IL2RA and IL7R by reducing available shared

regulatory miRNAs (42). C22orf29 (also known as RTL10) may have the capacity to induce apoptosis in a BH3 domain-dependent manner, presumably by engaging the Bcl2 family regulatory network to modulate the intrinsic apoptotic signaling pathway (43). The identification of known diagnostic biomarkers and immunotherapy targets within our predictive genes lends credence to the graphical models utilized in this study.

369 Given the cancer immunoprevention potential of the MUC1 peptide vaccine response, 370 characterized by a reduction of adenoma recurrence (14), the differentially expressed 371 genes and regulated pathways we identified hold promise as therapeutic targets for 372 vaccine non-responders. While these observations were made on responders and non-373 responders to the MUC1 vaccine, it is likely that a number of these differentially enriched 374 genes and pathways play a role in other vaccine responses. Many vaccines do not elicit 375 a response in all recipients, such as the yearly flu vaccine which varies in effectiveness 376 between 40% and 60% (44). The selected adjuvant for the MUC1 vaccine, polyICLC. 377 excels at activating dendritic cells to promote type I (innate) immunity (45). Alternative 378 adjuvants may need to be considered for non-responders to the MUC1 peptide 379 adjuvanted with polyICLC. While efforts are often made to improve the vaccine, it also 380 may be important to consider an individual's incoming immune history to respond to the 381 vaccine. Indeed, numerous research studies have demonstrated a correlation between 382 the immune status prior to vaccination and the subsequent antibody response (46, 47). 383 Overall, individuals that responded to the MUC1 vaccine showed a greater readiness in 384 all the immune compartments to present and respond to antigen. The ability to profile 385 individuals as potential responders or non-responders can aid in the selection of those 386 who benefit most from a particular vaccine. At the same time, understanding the barriers

- 387 to response in non-responders can inform the development of better vaccine designs
- 388 suitable for specific immune genotypes and phenotypes.

389 Authors' Disclosures

R.E. Schoen reports support from Freenome, Exact Sciences, and Immunovia during

the conduct of the study; in addition, R.E. Schoen has a patent for Anti-MUC1 Binding

392 Agent and Uses Thereof pending. O.J. Finn reports personal fees from PDS Biotech,

393 Invectys, Immodulon, and Ardigen outside the submitted work.

394395 Funding

- 396 This research was supported by NCI and NHLBI funding to OJF (R35CA210039), PVB
- (R01HL159805), and MJC (P30CA043703 Sub-Project 9164). VR was supported by a
 fellowship through the T32CA082084 grant.
- 399

400 Acknowledgements

401 We appreciate the tremendous efforts of the team members that conducted the two

- 402 clinical trials and provided samples for this study, particularly Lisa Boardman, Marcia
- 403 Cruz-Correa, Ajay Bansal, David Kastenberg, Chin Hur, Lynda Dzubinski, Sharon
- 404 Kaufman, Luz M Rodriguez, Ellen Richmond, Asad Umar, Eva Szabo, Andres Salazar,
- 405 John McKolanis, Pamela Beatty, Reetesh Pai, Aatur Singhi, Camille Jacqueline, Riyue
- 406 Bao, Brenda Diergaarde, Ryan McMurray, Carrie Strand, Nathan Foster, David Zahrieh,
- 407 and Paul Limburg. We are also indebted to all the trial participants for their commitment
- to our cancer prevention mission. We thank the Genomics Core at the Lerner Research
- 409 Institute of Cleveland Clinic and the Genomics and Applied Functional Genomics Cores
- 410 at Case Western Reserve University for their technical and analytical support.

411

413 Figure Legends

414 Figure 1: Differential gene expression pre- and post-MUC1 vaccination in 415 responders and non-responders. Differentially expressed genes (DEGs) are shown for 416 each time point and contrast in the left column, top 50 DEGs are shown in the right 417 column. Group status is indicated in the row above the heatmap with responders (R) in 418 dark blue, and non-responders (NR) in light blue. Z-scored normalized gene expression 419 for each gene is displayed horizontally across all samples (diverging color scale legend 420 on the upper right of each heatmap). Log2 fold-change and p values are indicated in the 421 purple and green vertical columns, respectively. Unsupervised clustering of the samples 422 is indicated by the black dendrogram at the top of heatmap, while clustering of the genes 423 is indicated at the far left. Heatmaps showing all DEGs pre-vaccination (Baseline/Week 424 0) (A), top 50 DEGs pre-vaccination (Baseline/Week 0) (B), DEGs at Week 2 post-425 vaccination (C), top 50 DEGs at Week 2 post-vaccination (D), all genes demonstrating 426 longitudinal changes at Week 2 vs. Week 0 (Delta Wk2-Wk0) (E), top 50 genes 427 demonstrating longitudinal changes at Week 2 vs. Week 0 (Delta Wk2-Wk0) (F) in 428 PBMCs from responders versus non-responders.

429

Figure 2: Differentially expressed T-cell fitness signatures in PBMCs from responders and non-responders to MUC1 vaccination is associated with CD4 frequencies and expression of multiple regulators of T-cell help. (A,B) iCOSL signaling pathway-related genes are associated with response to MUC1 vaccination at Baseline (A) and Week 2 post-vaccination (B) in MUC1 vaccine responders and nonresponders. Heatmaps are organized as in Figure 1. (C) Violin plots of CD4+ T-cell

frequencies as determined by flow cytometry. (D-F) Violin plots of CD40L expression on
CD4 T-cells (D), CD8 T-cells (E), and the change in ICOS levels on CD8 T-cells (Delta
Week 2 vs. Week 0/Baseline) (F) measured by geometric mean fluorescence intensity
(MFI).

440

441 Figure 3: The mTOR signaling pathway is upregulated in enhanced response to 442 **MUC1 vaccination.** (A) Heatmap showing top differentially enriched pathways from the 443 Hallmark Gene Set (MSigDB) in the PBMCs from high responders (HR) vs. non-444 responders (NR) at Baseline. Group status is indicated in the row above the heatmap as 445 follows: high responders (HR) - pink, while non-responders (NR) - light blue. Z-scored 446 normalized pathway enrichment log 2 fold-change and p values are displayed as in Figure 447 1. Unsupervised clustering of the samples is indicated at the top of the heatmap, while 448 clustering of the pathways is displayed on the far left. (B) Violin plots showing the level of 449 S6 ribosomal protein phosphorylation in the indicated cell subsets (CD4, CD8, CD19/B-450 cells and CD14/monocytes). (C) Violin plots showing the level of AKT1 phosphorylation 451 in the indicated cell subsets (CD4, CD8, CD19/B-cells and CD14/monocytes). For all 452 violin plots, geometric mean fluorescence intensity (MFI) is shown on the y-axis. 453 Responders (R) and non-responders (NR) are designated by dark blue and light blue 454 respectively.

455

Figure 4: B-cell signaling and NFκB signaling signatures are associated with
 response to MUC1 vaccination. (A,B) Heatmaps showing enrichment of B-Cell
 Receptor Signaling pathways in the PBMCs from Responders (R) vs. non-responders

(NR) at Baseline (A) and high responders (HR) vs. non-responders (NR) at Baseline (B).
(C,D) Differential gene expression from the CD40 Signaling pathway from PBMCs from
R vs. NR at Baseline (C) and Week 2 (D). Heat maps are organized as in Figure 1. (E)
Violin plots showing expression levels of CD40 and HLA-DR on B-cells (CD19+). (F)
Violin plots of NFκB complex p65 subunit phosphorylation in T-cells (CD3+), non-DC/nonB antigen presenting cells (CD11C-HLADR+), and B-cells (CD19+). For violin plots,
geometric mean fluorescence intensity (MFI) is shown on the y-axis.

466

Figure 5: Signatures of enhanced antigen presentation are evident in participants with an enhanced response to MUC1 vaccination. Heatmaps showing enrichment of dendritic cell (DC) specific genes in the PBMCs from Responders (R) vs. non-responders (NR) at Baseline (A) and Week 2 post-vaccination (B). Heatmaps are organized as in Figure 1. Violin plots of HLA-DR expression on DCs at Baseline (Week 0) (C), as well relative change in expression of CD86 (D) and CD40 (E) in these cells. For all violin plots, geometric mean fluorescence intensity (MFI) is shown on the y-axis.

474

Figure 6: Graphical models of response from transcriptomic data measured twoweeks post-vaccination. (A) Receiver Operating Characteristic curve of response (≥2fold increase in IgG) using week 2 transcriptome signature. (B) Correlation of predicted response odds with the magnitude of antibody titer at week 12 (C) Full model showing all neighbors and second neighbors of week 12 antibody titer levels (Week 12 IgG), (D) reduced model showing only direct causes of week 12 antibody titer. Color of edge denotes a positive vs negative correlation, and size denotes edge stability.

482 Supplemental Material

483 **Table 1:** Detailed information on antibody panels used for flow cytometric analysis.

485 **Supplemental Methods:**

486 Causal Modeling with MGM-FCI-MAX

A Probabilistic Graphical Model (PGM) represents the joint distribution of variables in a dataset as a graph where each node corresponds to a variable and an edge between two nodes, A and B, corresponds to a conditional dependence between A and B given the rest of the variables in the data (48). PGM's come in two types: directed graphical models rely on additional assumptions to infer cause and effect direction between variables, while undirected graphical models indicate only conditional dependence.

493 MGM-FCI-MAX is a new method to learn a directed model (17). The algorithm 494 begins by inferring an undirected graphical model using the Mixed Graphical Models 495 (MGM) algorithm (16) and then uses FCI-MAX to determine causal direction. MGM 496 models categorical variables as multinomial and continuous variables as Gaussian with 497 a mean given by a linear regression on all other variables. The full joint distribution of the 498 model is given in Equation 1 below. Here, x_s is the sth of p continuous y_i is the jth of q categorical variables. β_{st} is the linear interaction term between two continuous variables, 499 500 and α_s is the continuous node potential. ρ_{si} is the edge potential function between 501 continuous and categorical variables, and it takes on one value for each category of the variable y_i . Finally, ϕ_{rj} is the potential function between two categorical variables with a 502 503 unique value for all combinations of categories of the variables y_r and y_i .

504
$$p(x, y; \theta) \propto exp\left(\sum_{s=1}^{p} \sum_{t=1}^{p} -\frac{1}{2}\beta_{st}x_{s}x_{t} + \sum_{s=1}^{p} \alpha_{s}x_{s} + \right)$$

505
$$\sum_{s=1}^{p} \sum_{j=1}^{q} \rho_{sj}(y_j) x_s + \sum_{j=1}^{q} \sum_{r=1}^{q} \phi_{rj}(y_r, y_j)$$
(1)

506 The pseudolikelihood approach was used to optimize the model parameters (49). 507 The pseudolikelihood is the product of the conditional distributions of each variable, and

it is a consistent estimator of the goodness of fit of the model to the data. To ensure a sparse graph, edges are penalized via the method proposed in (16) with separate penalty parameters for each edge type: (CC = Continuous-Continuous, CD = Continuous-Discrete, DD= Discrete-Discrete) (Equation 2). Here, $\tilde{l}(\theta)$ is the negative-log pseudolikelihood and the rest are penalty terms which ensure a sparse model.

513
$$\operatorname{argmin}_{\Theta} \tilde{l}(\Theta) + \lambda_{CC} \sum_{\varphi < \omega} |\beta_{\varphi \omega}|_{1} + \lambda_{CD} \sum_{\omega, \tau} ||\rho_{\omega \tau}||_{2} + \lambda_{DD} \sum_{\delta < \omega} ||\gamma_{\delta \omega}||_{F}$$
(2)

514 FCI-MAX is used to determine causal directions using the undirected graph as a 515 starting point. FCI-MAX is an extension of the Fast-Causal Inference (FCI) algorithm (50), 516 which is a sound and complete constraint-based algorithm for learning the causal 517 structure of a set of variables in the presence of confounding variables. FCI uses 518 conditional independence tests to rule out unlikely cause and effect relationships. FCI-519 MAX improves the accuracy of FCI by performing additional tests to more accurately 520 assign orientations, especially in datasets with small sample sizes. The output of the 521 algorithm is a graphical causal model where there are four possible edges. An edge of 522 the form ("A --> B") suggests that A is a cause of B and B is not a cause of A. An edge 523 ("A <--> B") suggests that neither A nor B is a cause of the other, that is, a confounding 524 variable causes both. An edge ("A o--> B") suggests that if there are no latent variables 525 causing both A and B, then A is a cause of B. Finally, an edge of the form ("A o-o B") 526 suggests that both endpoints are inconclusive. In high dimensional datasets (small 527 sample size, large number of variables) these algorithms are less accurate in inferring 528 causal orientations as they are in inferring the presence or absence of an edge(17).

529 A likelihood ratio independence test (15) suitable for mixed data was used by FCI-530 MAX. All three sparsity parameters for MGM ($\lambda_{cc}, \lambda_{cD}, \lambda_{DD}$) were set to the default 0.2 and

 $\alpha = 0.1$ was used for the independence test threshold for FCI-MAX. MGM-FCI-MAX was run on 100 bootstrap samples of the data, and edges were included in the final model if they appeared in at least 10% of bootstrapped samples.

534

535 Computational Model Development and Evaluation

536 LASSO logistic regression (23) was used to develop a prediction model (select 537 genes and infer logistic regression coefficients) for a binary outcome of response defined 538 by the clinical trial endpoint (\geq 2-fold increase in IgG from baseline to week 12), using 539 transcriptomic data measured two-weeks post-vaccination (Week 2 data). To develop and 540 simultaneously evaluate model predictions, a nested leave-one-out cross validation 541 approach was used. Iteratively, each individual sample is used as an evaluation set with 542 the remaining samples used to learn model parameters. On each training set, a LASSO 543 logistic regression was performed with an internal leave-one-out cross validation to 544 choose the optimal sparsity penalty value (λ). The predictions on the single left-out 545 sample in each round of cross validation were then used for downstream analysis.

The Receiver Operator Characteristic (ROC) curve was calculated, and predictive accuracy of the model was measured using the area under the curve (AUC) of response vs. non-response, as well as sensitivity and specificity of predicted probabilities. Feature stability was measured to ensure that models remained similar across different crossvalidation iterations.

551 MGM-FCI-MAX was used to infer the variables directly linked to response, using 552 clinical data (age, sex, and BMI) and those genes selected by LASSO in the week 2 553 transcriptomic data in at least one of the ten folds. LASSO logistic regression was used

- 554 to build a predictive model of response in each cross-validation fold. All statistical analysis
- 555 was performed in R.

557 REFERENCES

558 Zitvogel L, Perreault C, Finn OJ, Kroemer G. Beneficial autoimmunity improves 1. 559 cancer prognosis. Nat Rev Clin Oncol. 2021;18(9):591-602. 560 2. Jacqueline C, Finn OJ. Antibodies specific for disease-associated antigens 561 (DAA) expressed in non-malignant diseases reveal potential new tumor-associated 562 antigens (TAA) for immunotherapy or immunoprevention. Semin Immunol. 563 2020;47:101394. 564 Finn OJ. Rammensee HG. Is It Possible to Develop Cancer Vaccines to 3. 565 Neoantigens, What Are the Major Challenges, and How Can These Be Overcome? 566 Neoantigens: Nothing New in Spite of the Name. Cold Spring Harb Perspect Biol. 567 2018;10(11). 568 Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, et al. Identifying 4. 569 baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J 570 Immunother Cancer. 2017;5:44. 571 Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising 5. 572 immuno-therapeutics: platforms and current progress. J Hematol Oncol. 2022;15(1):28. 573 Gordon B, Gadi VK. The Role of the Tumor Microenvironment in Developing 6. 574 Successful Therapeutic and Secondary Prophylactic Breast Cancer Vaccines. Vaccines 575 (Basel). 2020;8(3). 576 Kimura T, McKolanis JR, Dzubinski LA, Islam K, Potter DM, Salazar AM, et al. 7. 577 MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer 578 immunoprevention feasibility study. Cancer Prev Res (Phila). 2013;6(1):18-26. 579 Ramanathan RK, Lee KM, McKolanis J, Hitbold E, Schraut W, Moser AJ, et al. 8. 580 Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with 581 SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol 582 Immunother. 2005;54(3):254-64. 583 Pantuck AJ, van Ophoven A, Gitlitz BJ, Tso CL, Acres B, Squiban P, et al. Phase 9. 584 I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding 585 MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. J 586 Immunother. 2004;27(3):240-53. 587 Bartsch R, Singer CF, Pfeiler G, Hubalek M, Stoeger H, Pichler A, et al. 10. 588 Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide 589 and docetaxel: sequencing results from ABCSG-34. Br J Cancer. 2021;124(11):1795-590 802. 591 11. Schimanski CC, Kasper S, Hegewisch-Becker S, Schroder J, Overkamp F, 592 Kullmann F, et al. Adjuvant MUC vaccination with tecemotide after resection of 593 colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter 594 AIO phase II trial (LICC). Oncoimmunology. 2020;9(1):1806680. 595 Ma P, Beatty PL, McKolanis J, Brand R, Schoen RE, Finn OJ. Circulating 12. 596 Myeloid Derived Suppressor Cells (MDSC) That Accumulate in Premalignancy Share 597 Phenotypic and Functional Characteristics With MDSC in Cancer. Front Immunol. 598 2019;10:1401. 599 13. Lohmueller JJ, Sato S, Popova L, Chu IM, Tucker MA, Barberena R, et al. 600 Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-

specificity and immunotherapeutic potential. Sci Rep. 2016;6:31740.

Schoen RE, Boardman LA, Cruz-Correa M, Bansal A, Kastenberg D, Hur C, et
al. Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for
Prevention of Recurrent Colorectal Adenoma. Clin Cancer Res. 2023;29(9):1678-88.

5. Sedgewick AJ, Buschur K, Shi I, Ramsey JD, Raghu VK, Manatakis DV, et al.
Mixed graphical models for integrative causal analysis with application to chronic lung
disease diagnosis and prognosis. Bioinformatics. 2019;35(7):1204-12.

- 608 16. Sedgewick AJ, Shi I, Donovan RM, Benos PV. Learning mixed graphical models 609 with separate sparsity parameters and stability-based model selection. BMC
- 610 Bioinformatics. 2016;17 Suppl 5:175.
- 611 17. Raghu VK, Ramsey JD, Morris A, Manatakis DV, Sprites P, Chrysanthis PK, et
 612 al. Comparison of strategies for scalable causal discovery of latent variable models from
 613 mixed data. Int J Data Sci Anal. 2018;6(1):33-45.
- 614 18. Jiang H, Lei R, Ding SW, Zhu S. Skewer: a fast and accurate adapter trimmer for 615 next-generation sequencing paired-end reads. BMC Bioinformatics. 2014;15:182.
- 616 19. Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory 617 requirements. Nat Methods. 2015;12(4):357-60.
- 618 20. Yang J, Ding X, Sun X, Tsang SY, Xue H. SAMSVM: A tool for misalignment
 619 filtration of SAM-format sequences with support vector machine. J Bioinform Comput
 620 Biol. 2015;13(6):1550025.
- 621 21. Liao Y, Śmyth GK, Shi W. featureCounts: an efficient general purpose program 622 for assigning sequence reads to genomic features. Bioinformatics. 2014;30(7):923-30.
- Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for
 microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.
- 625 23. Tibshirani R. Regression shrinkage and selection via the lasso. Journal of the
 626 Royal Statistical Society: Series B (Methodological). 1996;58(1):267-88.
- 627 24. Wang XX, Fu L, Li X, Wu X, Zhu Z, Fu L, Dong JT. Somatic mutations of the
- mixed-lineage leukemia 3 (MLL3) gene in primary breast cancers. Pathol Oncol Res.
 2011;17(2):429-33.
- 630 25. Wysocka J, Myers MP, Laherty CD, Eisenman RN, Herr W. Human Sin3
- deacetylase and trithorax-related Set1/Ash2 histone H3-K4 methyltransferase are
 tethered together selectively by the cell-proliferation factor HCF-1. Genes Dev.
- 633 2003;17(7):896-911.
- 634 26. Shen K, Valenstein ML, Gu X, Sabatini DM. Arg-78 of Nprl2 catalyzes GATOR1-
- 635 stimulated GTP hydrolysis by the Rag GTPases. J Biol Chem. 2019;294(8):2970-5.
- 636 27. Pudakalakatti S, Titus M, Enriquez JS, Ramachandran S, Zacharias NM,
- 637 Shureiqi I, et al. Identifying the Metabolic Signatures of PPARD-Overexpressing Gastric
 638 Tumors. Int J Mol Sci. 2022;23(3).
- 639 28. Padua D, Pinto DF, Figueira P, Pereira CF, Almeida R, Mesquita P. HMGA1 Has
- 640 Predictive Value in Response to Chemotherapy in Gastric Cancer. Curr Oncol.641 2021;29(1):56-67.
- Lin Y, Lin L, Fu F, Wang C, Hu A, Xie J, et al. Quantitative proteomics reveals
 stage-specific protein regulation of triple negative breast cancer. Breast Cancer Res
 Treat. 2021;185(1):39-52.
- 645 30. Terribas E, Fernandez M, Mazuelas H, Fernandez-Rodriguez J, Biayna J, Blanco
- 646 I, et al. KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for
- 647 malignant peripheral nerve sheath tumors. Neurooncol Adv. 2020;2(Suppl 1):i62-i74.

648 Han J, Xie R, Yang Y, Chen D, Liu L, Wu J, Li S. CENPA is one of the potential 31. 649 key genes associated with the proliferation and prognosis of ovarian cancer based on 650 integrated bioinformatics analysis and regulated by MYBL2. Transl Cancer Res. 651 2021;10(9):4076-86. 652 32. Feng Y, Li F, Yan J, Guo X, Wang F, Shi H, et al. Pan-cancer analysis and 653 experiments with cell lines reveal that the slightly elevated expression of DLGAP5 is 654 involved in clear cell renal cell carcinoma progression. Life Sci. 2021;287:120056. 655 33. Ueda Y, Ooshio I, Fusamae Y, Kitae K, Kawaguchi M, Jingushi K, et al. AlkB 656 homolog 3-mediated tRNA demethylation promotes protein synthesis in cancer cells. 657 Sci Rep. 2017;7:42271. 658 34. Nakaya HI, Wrammert J, Lee EK, Racioppi L, Marie-Kunze S, Haining WN, et al. 659 Systems biology of vaccination for seasonal influenza in humans. Nat Immunol. 660 2011;12(8):786-95. 661 35. Sakai M, Shimokawa T, Kobayashi T, Matsushima S, Yamada Y, Nakamura Y, Furukawa Y. Elevated expression of C10orf3 (chromosome 10 open reading frame 3) is 662 663 involved in the growth of human colon tumor. Oncogene. 2006;25(3):480-6. 664 36. Jeffery J, Sinha D, Srihari S, Kalimutho M, Khanna KK. Beyond cytokinesis: the 665 emerging roles of CEP55 in tumorigenesis. Oncogene. 2016;35(6):683-90. 666 Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, et al. The 37. 667 GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. 668 Curr Protoc Bioinformatics. 2016;54:1 30 1-1 3. 669 Capece D, Verzella D, Fischietti M, Zazzeroni F, Alesse E. Targeting 38. costimulatory molecules to improve antitumor immunity. J Biomed Biotechnol. 670 671 2012;2012:926321. 672 Singh R, Kaul R, Kaul A, Khan K. A comparative review of HLA associations with 39. 673 hepatitis B and C viral infections across global populations. World J Gastroenterol. 674 2007;13(12):1770-87. 675 40. Tan L, Qin Y, Xie R, Xia T, Duan X, Peng L, et al. N6-methyladenosine-676 associated prognostic pseudogenes contribute to predicting immunotherapy benefits 677 and therapeutic agents in head and neck squamous cell carcinoma. Theranostics. 678 2022;12(17):7267-88. 679 Spurlock CF, 3rd, Tossberg JT, Guo Y, Collier SP, Crooke PS, 3rd, Aune TM. 41. 680 Expression and functions of long noncoding RNAs during human T helper cell 681 differentiation. Nat Commun. 2015;6:6932. 682 Zhang C, Dang D, Cong L, Sun H, Cong X. Pivotal factors associated with the 42. 683 immunosuppressive tumor microenvironment and melanoma metastasis. Cancer Med. 684 2021;10(14):4710-20. 685 43. Zhang X, Weng C, Li Y, Wang X, Jiang C, Li X, et al. Human Bop is a novel BH3-686 only member of the Bcl-2 protein family. Protein Cell. 2012;3(10):790-801. 687 Smith DJ, Forrest S, Ackley DH, Perelson AS. Variable efficacy of repeated 44. 688 annual influenza vaccination. Proc Natl Acad Sci U S A. 1999;96(24):14001-6. 689 45. Caskey M, Lefebvre F, Filali-Mouhim A, Cameron MJ, Goulet JP, Haddad EK, et 690 al. Synthetic double-stranded RNA induces innate immune responses similar to a live 691 viral vaccine in humans. J Exp Med. 2011;208(12):2357-66. 692 46. Team H-CSP, Consortium H-I. Multicohort analysis reveals baseline 693 transcriptional predictors of influenza vaccination responses. Sci Immunol. 2017;2(14).

- Fourati S, Tomalin LE, Mule MP, Chawla DG, Gerritsen B, Rychkov D, et al. Pan vaccine analysis reveals innate immune endotypes predictive of antibody responses to
- 696 vaccination. Nat Immunol. 2022;23(12):1777-87.
- 697 48. Koller D, Friedman, N. Probabilistic graphical models: principles and techniques:698 MIT press; 2009.
- 699 49. Lee JD, Hastie TJ. Learning the Structure of Mixed Graphical Models. J Comput 700 Graph Stat. 2015;24(1):230-53.
- 50. Spirtes P, Meek C, Richardson T, editors. Causal inference in the presence of
- 702 latent variables and selection bias. Proceedings of the Eleventh conference on
- 703 Uncertainty in artificial intelligence; 1995: Morgan Kaufmann Publishers Inc.
- 704



Figure 2 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 3 medRxiv preprint doi: https://doi.org/10.1101/2024.05.09.24305336; this version posted May 10, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .





R







Figure 6 medRxiv preprint doi: https://doi.org/10.1101/2024.05.09.24305336; this version posted May 10, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Supplemental Table 1

Panel 1: Innate Phenotyping

Company	Cat #	Antibody	Color
BD	560114	STAT3 (pY705)	PerCP-Cy5.5
BD	558421	anti-NF-кВ p65 (pS529)	A488
BD	563931	CD152/CTLA4	BV786
Biolegend	305440	CD86	BV711
BD	743008	CD275/ICOSLG	BV650
BD	563929	CD11c	BV605
Invitrogen	L34957	Live/Dead	Amcyan
Biolegend	318340	CD56	BV510
BD	558122	CD16	PB
BD	564303	CD19	BUV737
BD	563546	CD3	BUV395
BD	335796	HLA-DR	APC Cy7
BD	557923	CD14	A700
BD	612593	Anti-ERK1/2 (pT202/pY204)	APC
Biolegend	334321	CD40	PE-Cy7
BD	563601	BCL-2	PE-CF594
BD	555388	CD11b	PE

Panel 2: MTOR Signaling

Company	Cat #	Antibody (Clone)	Color
BD	338426	CD16	PerCP-Cy5.5
BD	560048	anti-Akt1 (PKBa/Akt)	FITC
BD	564058	CD56	BV786
BD	563677	CD8	BV711
Biolegend	304135	CD45RA	BV650
Invitrogen	Q10008	CD4	Q.605
Invitrogen	L34957	Live/Dead	Amcyan
Biolegend	302242	CD19	BV510
BD	561457	pS6 (S235/S236)	V450
BD	564444	CD14	BUV737
BD	565885	Anti-ICOS (CD278)	BUV395
BD	563588	Anti-Human CD154 (CD40L)	APCeFluor780
BD	557943	CD3	A700
BD	560432	Anti-S6 pS240	A647
BD	562321	CD19	PE-CF594
BD	560684	Anti-Human CD28	PE-Cy7
BD	560285	p4E-BP1 (T36/46)	PE